Novo Nordisk (NVO) Stock Climbs as Company Launches Trial for Lower-Dose Wegovy Pills
Novo Nordisk (NVO) stock gains as the pharma giant starts a trial testing lower Wegovy doses, with Q2 sales reaching $500M and 5M+ prescriptions filled.
The post Novo Nordisk (NVO) Stock Climbs as Company Launches Trial for Lower-Dose Wegovy Pills appeared first on Blockonomi.
Source: Source: Blockonomi